Trials / Terminated
TerminatedNCT00463723
Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- University Hospital Freiburg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Background: Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions. Steroids are known to yield good results, but exert a wide range of side effects. The efficacy of topial FK506 in preventing immune reactions has already been demonstrated experimentally. FK506, an IL-2-inhibitor like Cyclosporin A (CSA), is known to be approximately 100 fold more potent than CSA. Aim of the study: In this study the efficacy and safety of topical FK506 will be compared to our standard treatment (i.e. steroids) after penetrating normal-risk keratoplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FK506 0.06% (eye drops) |
Timeline
- First posted
- 2007-04-20
- Last updated
- 2007-04-20
Source: ClinicalTrials.gov record NCT00463723. Inclusion in this directory is not an endorsement.